Univariate and multivariate LR models for thrombosis risk
| . | Univariate . | Multivariate . | ||||
|---|---|---|---|---|---|---|
| OR . | 95% CI . | P value . | OR . | 95% CI . | P value . | |
| Age | 1.01 | (0.97-1.06) | .51 | 1.00 | (0.95-1.05) | .98 |
| UBA1 mutation | ||||||
| T | — | — | — | — | ||
| L | 0.86 | (0.29-2.60) | .79 | 1.03 | (0.28-3.77) | .97 |
| V | 0.69 | (0.19-2.40) | .56 | 0.52 | (0.17-1.56) | .24 |
| C | 0.25 | (0.01-2.18) | .26 | 0.23 | (0.02-2.62) | .23 |
| MDS | 0.76 | (0.34-1.67) | .50 | 1.03 | (0.42-2.50) | .95 |
| Plasma cell dyscrasia | 0.95 | (0.36-2.45) | .91 | 0.66 | (0.22-1.94) | .45 |
| RP dx | 1.02 | (0.49-2.11) | .97 | 0.47 | (0.16-1.38) | .17 |
| Sweet syndrome | 0.89 | (0.27-2.85) | .84 | 0.48 | (0.12-1.92) | .30 |
| Systemic involvement | 3.63 | (1.39-10.74) | .012 | 2.99 | (0.95-9.36) | .06 |
| Skin involvement | 1.60 | (0.70-3.79) | .27 | 1.46 | (0.53-4.04) | .47 |
| Cardiac manifestations | 6.92 | (1.13-133.01) | .08 | 5.87 | (0.59-58.80) | .13 |
| Ear or nose chondritis | 1.90 | (0.92-4.02) | .09 | 2.29 | (0.83, 6.35) | .11 |
| Musculoskeletal | 1.15 | (0.54-2.45) | .72 | 0.99 | (0.40-2.42) | .98 |
| Pulmonary manifestations | 2.34 | (1.13-4.94) | .024 | 1.49 | (0.60-3.68) | .39 |
| . | Univariate . | Multivariate . | ||||
|---|---|---|---|---|---|---|
| OR . | 95% CI . | P value . | OR . | 95% CI . | P value . | |
| Age | 1.01 | (0.97-1.06) | .51 | 1.00 | (0.95-1.05) | .98 |
| UBA1 mutation | ||||||
| T | — | — | — | — | ||
| L | 0.86 | (0.29-2.60) | .79 | 1.03 | (0.28-3.77) | .97 |
| V | 0.69 | (0.19-2.40) | .56 | 0.52 | (0.17-1.56) | .24 |
| C | 0.25 | (0.01-2.18) | .26 | 0.23 | (0.02-2.62) | .23 |
| MDS | 0.76 | (0.34-1.67) | .50 | 1.03 | (0.42-2.50) | .95 |
| Plasma cell dyscrasia | 0.95 | (0.36-2.45) | .91 | 0.66 | (0.22-1.94) | .45 |
| RP dx | 1.02 | (0.49-2.11) | .97 | 0.47 | (0.16-1.38) | .17 |
| Sweet syndrome | 0.89 | (0.27-2.85) | .84 | 0.48 | (0.12-1.92) | .30 |
| Systemic involvement | 3.63 | (1.39-10.74) | .012 | 2.99 | (0.95-9.36) | .06 |
| Skin involvement | 1.60 | (0.70-3.79) | .27 | 1.46 | (0.53-4.04) | .47 |
| Cardiac manifestations | 6.92 | (1.13-133.01) | .08 | 5.87 | (0.59-58.80) | .13 |
| Ear or nose chondritis | 1.90 | (0.92-4.02) | .09 | 2.29 | (0.83, 6.35) | .11 |
| Musculoskeletal | 1.15 | (0.54-2.45) | .72 | 0.99 | (0.40-2.42) | .98 |
| Pulmonary manifestations | 2.34 | (1.13-4.94) | .024 | 1.49 | (0.60-3.68) | .39 |
C, splice site mutations; dx, diagnosis; L, leucine; RP, relapsing polychondritis; T, threonine; V, valine.